$MHTX
MANHATTAN SCIENTIFICS INC

2024 Q2 Form 10-Q Financial Statement

#000147793224002983 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $158.0K $189.0K $186.0K
YoY Change -12.71% 1.61% 3.33%
% of Gross Profit
Research & Development $2.000K $3.000K $0.00
YoY Change -60.0% -100.0%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit
Operating Expenses $160.0K $192.0K $186.0K
YoY Change -13.98% 3.23% 6100.0%
Operating Profit -$160.0K -$192.0K -$186.0K
YoY Change -13.98% 3.23% 1.64%
Interest Expense $2.000K -$190.0K -$249.0K
YoY Change -23.69% -46.34%
% of Operating Profit
Other Income/Expense, Net $2.000K -$190.0K -$234.0K
YoY Change -104.65% -18.8% -49.57%
Pretax Income -$158.0K -$382.0K -$420.0K
YoY Change -31.0% -9.05% -35.09%
Income Tax
% Of Pretax Income
Net Earnings -$158.0K -$382.0K -$420.0K
YoY Change -31.0% -9.05% -35.09%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 559.3M shares 559.3M shares 559.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.00K $51.00K $90.00K
YoY Change -26.92% -43.33% -25.62%
Cash & Equivalents $38.00K $51.00K $90.00K
Short-Term Investments
Other Short-Term Assets $7.000K $9.000K $25.00K
YoY Change -22.22% -64.0% 31.58%
Inventory
Prepaid Expenses $7.000K $9.000K
Receivables
Other Receivables
Total Short-Term Assets $45.00K $60.00K $115.0K
YoY Change -26.23% -47.83% -73.86%
LONG-TERM ASSETS
Property, Plant & Equipment $1.000K
YoY Change -66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $27.00K $29.00K $576.0K
YoY Change -94.66% -94.97% -76.43%
Other Assets $2.000K $2.000K $2.000K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $29.00K $31.00K $579.0K
YoY Change -94.29% -94.65% -76.36%
TOTAL ASSETS
Total Short-Term Assets $45.00K $60.00K $115.0K
Total Long-Term Assets $29.00K $31.00K $579.0K
Total Assets $74.00K $91.00K $694.0K
YoY Change -86.99% -86.89% -75.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $156.0K $147.0K $134.0K
YoY Change 24.8% 9.7% 25.23%
Accrued Expenses $2.180M $2.048M $1.537M
YoY Change 32.12% 33.25% 27.98%
Deferred Revenue
YoY Change
Short-Term Debt $60.00K $60.00K $70.00K
YoY Change -14.29% -14.29% -48.15%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.416M $2.275M $1.751M
YoY Change 30.24% 29.93% 21.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.416M $2.275M $1.751M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.416M $2.275M $1.751M
YoY Change 30.24% 29.93% 21.34%
SHAREHOLDERS EQUITY
Retained Earnings -$72.96M -$72.80M
YoY Change 1.47%
Common Stock $559.0K $559.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.400M -$3.242M -$1.057M
YoY Change
Total Liabilities & Shareholders Equity $74.00K $91.00K $694.0K
YoY Change -86.99% -86.89% -75.98%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$158.0K -$382.0K -$420.0K
YoY Change -31.0% -9.05% -35.09%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$17.00K -$42.00K -$75.00K
YoY Change -73.44% -44.0% -32.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.000K $26.00K $0.00
YoY Change -84.62%
Cash From Investing Activities $4.000K $26.00K $0.00
YoY Change -84.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00 -10.00K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -17.00K -$42.00K -75.00K
Cash From Investing Activities 4.000K $26.00K 0.000
Cash From Financing Activities 0.000 $0.00 -10.00K
Net Change In Cash -13.00K -$16.00K -85.00K
YoY Change -65.79% -81.18% -23.42%
FREE CASH FLOW
Cash From Operating Activities -$17.00K -$42.00K -$75.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-382000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3242000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-382000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-420000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
CY2023Q4 us-gaap Assets Current
AssetsCurrent
69000 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
245000.00 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2115000 usd
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001099132
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
MANHATTAN SCIENTIFICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity File Number
EntityFileNumber
000-28411
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0460639
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
244 Fifth Ave
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2341
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
CY2024Q1 dei City Area Code
CityAreaCode
212
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
541-2405
CY2024Q1 dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
559281064 shares
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
60000 usd
CY2024Q1 us-gaap Equity Method Investments
EquityMethodInvestments
29000 usd
CY2024Q1 us-gaap Other Assets
OtherAssets
2000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
2000.00 usd
CY2024Q1 us-gaap Assets
Assets
91000 usd
CY2023Q4 us-gaap Assets
Assets
316000 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
147000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
133000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2048000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1915000 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
20000 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
10000 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
60000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
60000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2275000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2118000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
2275000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2118000 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q1 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
1058000 usd
CY2023Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
1058000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
559000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
559000 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
68996000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
68996000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72797000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72415000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3242000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2860000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
316000 usd
CY2024Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
189000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
186000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
192000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
186000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-192000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-186000 usd
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-190000 usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-249000 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-190000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-234000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-382000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-420000 usd
CY2024Q1 mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
CY2023Q1 mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
CY2024Q1 mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
CY2023Q1 mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2860000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1695000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-420000 usd
CY2024Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-190000 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-249000 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
11000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
14000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
14000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
133000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
98000 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75000 usd
CY2024Q1 us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
26000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-85000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90000 usd
CY2024Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2024Q1 mhtx Investment In Equity Shares Transferred To Pay Note Down
InvestmentInEquitySharesTransferredToPayNoteDown
0 usd
CY2023Q1 mhtx Investment In Equity Shares Transferred To Pay Note Down
InvestmentInEquitySharesTransferredToPayNoteDown
30000 usd
CY2024Q1 mhtx Common Stock Owned Share
CommonStockOwnedShare
591662 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
559281064 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72797000 usd
CY2024Q1 mhtx Working Capital
WorkingCapital
-2215000 usd
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q1 us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
0 usd
CY2024Q1 us-gaap Investments
Investments
29000 usd
CY2023Q4 us-gaap Investments
Investments
245000 usd
CY2024Q1 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained
CY2024Q1 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
28922917 shares
CY2023Q1 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
26655760 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-382000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-420000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
CY2024Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
559281064 shares
CY2023Q4 us-gaap Investments
Investments
245000 usd
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-190000 usd
CY2024Q1 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
26000 usd
CY2024Q1 us-gaap Investments
Investments
29000 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.04
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.08
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
26500000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 mhtx Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice
0.04
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
26500000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
CY2024Q1 mhtx Royalty Percentage On Dental Products
RoyaltyPercentageOnDentalProducts
0.10 pure
CY2024Q1 mhtx Royalty Percentage On Other Licensed Products
RoyaltyPercentageOnOtherLicensedProducts
0.05 pure
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
20000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2048000 usd

Files In Submission

Name View Source Status
0001477932-24-002983-index-headers.html Edgar Link pending
0001477932-24-002983-index.html Edgar Link pending
0001477932-24-002983.txt Edgar Link pending
0001477932-24-002983-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mhtx-20240331.xsd Edgar Link pending
mhtx_10q.htm Edgar Link pending
mhtx_ex311.htm Edgar Link pending
mhtx_ex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mhtx-20240331_cal.xml Edgar Link unprocessable
mhtx-20240331_def.xml Edgar Link unprocessable
mhtx-20240331_lab.xml Edgar Link unprocessable
mhtx-20240331_pre.xml Edgar Link unprocessable
mhtx_10q_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending